Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian J Majewski

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Blood|February 4, 2015
Jarid2 regulates hematopoietic stem cell function by acting with polycomb repressive complex 2Sarah A Kinkel, Roman Galeev, Christoffer Flensburg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2020
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive ChemotherapyChong Chyn Chua, Andrew W Roberts, John Reynolds, et al.
Breast Cancer Research : BCR|August 31, 2017
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant settingTesa M Severson, Denise M Wolf, Christina Yau, et al.
Blood|April 13, 2016
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Jing Deng, John F Seymour, et al.
EMBO Reports|February 23, 2017
A non-canonical function of Ezh2 preserves immune homeostasisAjithkumar Vasanthakumar, Dakang Xu, Aaron Tl Lun, et al.
Blood Advances|March 10, 2020
The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemiaLauren M Brown, Andrew Lonsdale, Andrea Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancerIan J Majewski, Paolo Nuciforo, Lorenza Mittempergher, et al.
Blood|July 28, 2018
MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AMLMathijs A Sanders, Edward Chew, Christoffer Flensburg, et al.
Cancer Discovery|December 6, 2018
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic LeukemiaPiers Blombery, Mary Ann Anderson, Jia-Nan Gong, et al.
Blood|June 16, 2022
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapyRachel Thijssen, Luyi Tian, Mary Ann Anderson, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Blood|February 4, 2015
Jarid2 regulates hematopoietic stem cell function by acting with polycomb repressive complex 2Sarah A Kinkel, Roman Galeev, Christoffer Flensburg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2020
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive ChemotherapyChong Chyn Chua, Andrew W Roberts, John Reynolds, et al.
Breast Cancer Research : BCR|August 31, 2017
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant settingTesa M Severson, Denise M Wolf, Christina Yau, et al.
Blood|April 13, 2016
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Jing Deng, John F Seymour, et al.
EMBO Reports|February 23, 2017
A non-canonical function of Ezh2 preserves immune homeostasisAjithkumar Vasanthakumar, Dakang Xu, Aaron Tl Lun, et al.
Blood Advances|March 10, 2020
The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemiaLauren M Brown, Andrew Lonsdale, Andrea Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancerIan J Majewski, Paolo Nuciforo, Lorenza Mittempergher, et al.
Blood|July 28, 2018
MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AMLMathijs A Sanders, Edward Chew, Christoffer Flensburg, et al.
Cancer Discovery|December 6, 2018
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic LeukemiaPiers Blombery, Mary Ann Anderson, Jia-Nan Gong, et al.
Blood|June 16, 2022
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapyRachel Thijssen, Luyi Tian, Mary Ann Anderson, et al.
Pageof 5